|
1
|
Kessis TD, Slebos RJ, Nelson WG, et al:
Human papillomavirus 16 E6 expression disrupts the p53-mediated
cellular response to DNA damage. Proc Natl Acad Sci USA.
90:3988–3992. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nees M, Geoghegan JM, Munson P, et al:
Human papillomavirus type 16 E6 and E7 proteins inhibit
differentiation-dependent expression of transforming growth
factor-β2 in cervical keratinocytes. Cancer Res. 60:4289–4298.
2000.PubMed/NCBI
|
|
3
|
Parkin DM, Pisani P and Ferlay J:
Estimates of the worldwide incidence of eighteen major cancers in
1985. Int J Cancer. 54:594–606. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Runowicz CD, Wadler S, Rodriguez-Rodriguez
L, et al: Concomitant cisplatin and radiotherapy in locally
advanced cervical carcinoma. Gynecol Oncol. 34:395–401. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alberts DS, Garcia D and Mason-Liddil N:
Cisplatin in advanced cancer of the cervix: an update. Semin Oncol.
18:11–24. 1991.PubMed/NCBI
|
|
6
|
Malfetano J, Keys H, Kredentser D,
Cunningham M, Kotlove D and Weiss L: Weekly cisplatin and radical
radiation therapy for advanced, recurrent, and poor prognosis
cervical carcinoma. Cancer. 71:3703–3706. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Whitney CW, Sause W, Bundy BN, et al:
Randomized comparison of fluorouracil plus cisplatin versus
hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA
carcinoma of the cervix with negative para-aortic lymph nodes: a
Gynecologic Oncology Group and Southwest Oncology Group study. J
Clin Oncol. 17:1339–1348. 1999.
|
|
8
|
Sorbe B, Bohr L, Karlsson L and Bermark B:
Combined external and intracavitary irradiation in treatment of
advanced cervical carcinomas: Predictive factors for local tumor
control and early recurrences. Int J Oncol. 36:371–378. 2010.
|
|
9
|
Morris M, Eifel PJ, Lu J, et al: Pelvic
radiation with concurrent chemotherapy compared with pelvic and
para-aortic radiation for high-risk cervical cancer. N Engl J Med.
340:1137–1143. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rose PG, Bundy BN, Watkins EB, et al:
Concurrent cisplatin-based radiotherapy and chemotherapy for
locally advanced cervical cancer. N Engl J Med. 340:1144–1153.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Eifel PJ, Winter K, Morris M, et al:
Pelvic irradiation with concurrent chemotherapy versus pelvic and
para-aortic irradiation for high-risk cervical cancer: an update of
radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol.
22:872–880. 2004. View Article : Google Scholar
|
|
12
|
Vokes EE and Weichselbaum RR: Concomitant
chemoradiotherapy: rationale and clinical experience in patients
with solid tumors. J Clin Oncol. 8:911–934. 1990.PubMed/NCBI
|
|
13
|
Tannock IF: Treatment of cancer with
radiation and drugs. J Clin Oncol. 14:3156–3174. 1996.PubMed/NCBI
|
|
14
|
Randall LM, Monk BJ, Moon J, et al:
Prospective evaluation of an in vitro radiation resistance assay in
locally advanced cancer of the uterine cervix: a Southwest Oncology
Group Study. Gynecol Oncol. 119:417–421. 2010. View Article : Google Scholar
|
|
15
|
Tanaka T, Bai T, Yukawa K and Umesaki N:
Optimal combination chemotherapy and chemoradiotherapy with
etoposide for advanced cervical squamous cancer cells in
vitro. Oncol Rep. 15:939–947. 2006.PubMed/NCBI
|
|
16
|
Tanaka T, Yukawa K and Umesaki N:
Radiation reduces carboplatin sensitivity and enhances nedaplatin
sensitivity in cervical squamous cell carcinoma in vitro. Eur J
Gynaecol Oncol. 28:352–355. 2007.
|
|
17
|
Egwuagu CE, Li W, Yu CR, et al:
Interferon-γ induces regression of epithelial cell carcinoma:
critical roles of IRF-1 and ICSBP transcription factors. Oncogene.
25:3670–3679. 2006.
|
|
18
|
Zheng HC, Nakamura T, Zheng Y, et al: SV40
T antigen disrupted the cell metabolism and the balance between
proliferation and apoptosis in lens tumors of transgenic mice. J
Cancer Res Clin Oncol. 135:1521–1532. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fujii M, Ide A, Nakabayashi K, Joguchi A,
Ogino H and Ayusawa D: The introduction of dominant-negative p53
mutants suppresses temperature shift-induced senescence in immortal
human fibroblasts expressing a thermolabile SV40 large T antigen. J
Biochem. 125:531–536. 1999. View Article : Google Scholar
|
|
20
|
Dueñas-González A, Cetina-Perez L,
Lopez-Graniel C, et al: Pathologic response and toxicity assessment
of chemoradiotherapy with cisplatin versus cisplatin plus
gemcitabine in cervical cancer: a randomized Phase II study. Int J
Radiat Oncol Biol Phys. 61:817–823. 2005.PubMed/NCBI
|
|
21
|
Verbraecken J, Van de Heyning P, De Backer
W and Van Gaal L: Body surface area in normal-weight, overweight,
and obese adults. A comparison study. Metabolism. 55:515–524. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kumar L, Kaushal R, Nandy M, et al:
Chemotherapy followed by radiotherapy versus radiotherapy alone in
locally advanced cervical cancer: a randomized study. Gynecol
Oncol. 54:307–315. 1994. View Article : Google Scholar
|
|
23
|
Tattersall MH, Lorvidhaya V, Vootiprux V,
et al: Randomized trial of epirubicin and cisplatin chemotherapy
followed by pelvic radiation in locally advanced cervical cancer.
Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology
Association. J Clin Oncol. 13:444–451. 1995.
|
|
24
|
Sundfør K, Tropé CG, Högberg T, et al:
Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A
randomized multicenter study of sequential cisplatin and
5-fluorouracil and radiotherapy in advanced cervical carcinoma
stage 3B and 4A. Cancer. 77:2371–2378. 1996.
|
|
25
|
Shueng PW, Hsu WL, Jen YM, Wu CJ and Liu
HS: Neoadjuvant chemotherapy followed by radiotherapy should not be
a standard approach for locally advanced cervical cancer. Int J
Radiat Oncol Biol Phys. 40:889–896. 1998. View Article : Google Scholar
|
|
26
|
Neoadjuvant Chemotherapy for Locally
Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant
chemotherapy for locally advanced cervical cancer: a systematic
review and meta-analysis of individual patient data from 21
randomised trials. Eur J Cancer. 39:2470–2486. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grégoire V, Hunter NR, Brock WA, Hittelman
WN, Plunkett W and Milas L: Improvement in the therapeutic ratio of
radiotherapy for a murine sarcoma by indomethacin plus fludarabine.
Radiat Res. 146:548–553. 1996.
|
|
28
|
Milas L, Hunter N, Mason KA, Milross C and
Peters LJ: Tumor reoxygenation as a mechanism of taxol-induced
enhancement of tumor radioresponse. Acta Oncol. 34:409–412. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Milross CG, Mason KA, Hunter NR, et al:
Enhanced radioresponse of paclitaxel-sensitive and-resistant
tumours in vivo. Eur J Cancer. 33:1299–1308. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Suzuki M, Nakamatsu K, Kanamori S,
Masunaga S and Nishimura Y: Additive effects of radiation and
docetaxel on murine SCCVII tumors in vivo: special reference to
changes in the cell cycle. Radiat Res. 159:799–804. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Singh RB, Chander S, Mohanti BK, et al:
Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin
followed by chemoradiation in locally advanced cervical carcinoma:
a pilot study. Gynecol Oncol. 129:124–128. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
McCormack M, Kadalayil L, Hackshaw A, et
al: A phase II study of weekly neoadjuvant chemotherapy followed by
radical chemoradiation for locally advanced cervical cancer. Br J
Cancer. 108:2464–2469. 2013. View Article : Google Scholar
|
